A roundup of scientific studies on the novel coronavirus and efforts to find treatments and vaccines includes research on Covid-19 patients who still have symptoms 6 months after falling ill.

A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.

AstraZeneca, which is jointly developing a Covid-19 vaccine with the University of Oxford, plans to begin clinical trials testing the company’s vaccine in combination with Russia’s Sputnik V vaccine by the end of 2020.

AstraZeneca and Oxford University have more work to do to confirm whether their Covid-19 vaccine can be 90% effective, peer-reviewed data published in The Lancet showed, potentially slowing its eventual rollout in the fight against the pandemic.

A roundup of some of the latest scientific studies on the novel coronavirus includes research on whether a childhood vaccine may help prevent severe Covid-19 and whether cigarette smoke increases cell vulnerability to Covid-19.

Russia’s Sputnik V vaccine is 92% effective at protecting people from Covid-19 according to interim trial results, the country’s sovereign wealth fund said, as Moscow rushes to keep pace with Western drugmakers in the race for a shot.

The world is caught in a perfect storm of rising rates of chronic disease, persistent infectious diseases and public health failures that have fuelled deaths in the Covid-19 pandemic, according to a major global study of human health.

Political polarization and online misinformation are threatening vaccination programs worldwide, with public trust volatile and varying widely between countries, according to a global vaccine confidence study.

Russia’s “Sputnik-V” Covid-19 vaccine produced an antibody response in all participants in early-stage trials, according to results published by The Lancet medical journal.

The University of Oxford suggested that the end of 2020 is possible for the availability of a Covid-19 vaccine candidate being developed with AstraZeneca, but expressed caution about the timeline.